EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Anti‐apoptotic protein BCL‐XL as a therapeutic vulnerability in gastric cancer

Yumin Wei iD, Liping Zhang, Chao Wang, Zefeng Li, Mingjie Luo, Guomin Xie, Xingjiu Yang, Mengyuan Li, Shuyue Ren, Dongbing Zhao, Ran Gao, Jia-Nan Gong

Animal Models and Experimental Medicine · 2023

DOI: 10.1002/ame2.12330 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Animal Models and Experimental Medicine, 2023. Verfasst von Yumin Wei und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Human Diseases Animal Model Resource Center, The Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences & Peking Union …. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Nova Program, CAMS Innovation Fund for Medical Sciences (CIFMS), National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

New therapeutic targets are needed to improve the outcomes for gastric cancer (GC) patients with advanced disease. Evasion of programmed cell death (apoptosis) is a hallmark of cancer cells and direct induction of apoptosis by targeting the pro‐survival BCL2 family proteins represents a promising therapeutic strategy for cancer treatment. Therefore, understanding the molecular mechanisms underpinning cancer cell survival could provide a molecular basis for potential therapeutic interventions.

Method

Here we explored the role of BCL2L1 and the encoded anti‐apoptotic BCL‐XL in GC. Using Droplet Digital PCR (ddPCR) technology to investigate the DNA amplification of BCL2L1 in GC samples and GC cell lines, the sensitivity of GC cell lines to selective BCL‐XL inhibitors A1155463 and A1331852, pan‐inhibitor ABT‐263, and VHL‐based PROTAC‐BCL‐XL was analyzed using (CellTiter‐Glo) CTG assay in vitro. Western Blot (WB) was used to detect the protein expression of BCL2 family members in GC cell lines and the manner in which PROTAC‐BCL‐XL kills GC cells. Co‐immunoprecipitation (Co‐IP) was used to investigate the mechanism of A1331852 and ABT‐263 kills GC cell lines. DDPCR, WB, and real‐time PCR (RTPCR) were used to investigate the correlation between DNA, RNA, protein levels, and drug activity.

Results

The functional assay showed that a subset of GC cell lines relies on BCL‐XL for survival. In gastric cancer cell lines, BCL‐XL inhibitors A1155463 and A1331852 are more sensitive than the pan BCL2 family inhibitor ABT‐263, indicating that ABT‐263 is not an optimal inhibitor of BCL‐XL. VHL‐based PROTAC‐BCL‐XL DT2216 appears to be active in GC cells. DT2216 induces apoptosis of gastric cancer cells in a time‐ and dose‐dependent manner through the proteasome pathway. Statistical analysis showed that the BCL‐XL protein level predicts the response of GC cells to BCL‐XL targeting therapy and BCL2L1 gene CNVs do not reliably predict BCL‐XL expression.

Conclusion

We identified BCL‐XL as a promising therapeutic target in a subset of GC cases with high levels of BCL‐XL protein expression. Functionally, we demonstrated that both selective BCL‐XL inhibitors and VHL‐based PROTAC BCL‐XL can potently kill GC cells that are reliant on BCL‐XL for survival. However, we found that BCL2L1 copy number variations (CNVs) cannot reliably predict BCL‐XL expression, but the BCL‐XL protein level serves as a useful biomarker for predicting the sensitivity of GC cells to BCL‐XL‐targeting compounds. Taken together, our study pinpointed BCL‐XL as potential druggable target for specific subsets of GC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsAntineoplastic AgentsHumansbcl-X ProteinApoptosis Regulatory ProteinsDNA Copy Number VariationsProteolysis Targeting ChimeraCell Line, TumorProto-Oncogene Proteins c-bcl-2Aniline CompoundsSulfonamides

Stichwörter der Autor:innen

BCL2L1 (BCL-XL)PROTAC-BCL-XLapoptosisgastric cancer (GC)selective BCL-XL inhibitors

Substanzen

bcl-X ProteinApoptosis Regulatory ProteinsProteolysis Targeting ChimeraProto-Oncogene Proteins c-bcl-2Antineoplastic AgentsnavitoclaxAniline CompoundsSulfonamides

Autor:innen und Institutionen

  • National Human Diseases Animal Model Resource Center, The Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Beijing, China.
  • Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Beijing, China.
  • Department of Pancreatic and Gastric Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing,…
  • State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China.

ORCID-Profile: Yumin Wei

Förderung

  • Beijing Nova Program
  • CAMS Innovation Fund for Medical Sciences (CIFMS)
  • National Key Research and Development Program of China
  • Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
  • National Basic Research Program of China

Zitieren

APA

Wei, Y., Zhang, L., Wang, C., Li, Z., Luo, M., Xie, G., Yang, X., Li, M., Ren, S., Zhao, D., Gao, R., & Gong, J. N. (2023). Anti‐apoptotic protein BCL‐XL as a therapeutic vulnerability in gastric cancer. Animal Models and Experimental Medicine. https://doi.org/10.1002/ame2.12330

Vancouver

Wei Y, Zhang L, Wang C, Li Z, Luo M, Xie G, et al. Anti‐apoptotic protein BCL‐XL as a therapeutic vulnerability in gastric cancer. Animal Models and Experimental Medicine. 2023. doi:10.1002/ame2.12330

BibTeX
@article{Wei2023,
  author = {Wei, Yumin and Zhang, Liping and Wang, Chao and Li, Zefeng and Luo, Mingjie and Xie, Guomin and Yang, Xingjiu and Li, Mengyuan and Ren, Shuyue and Zhao, Dongbing and Gao, Ran and Gong, Jia-Nan},
  title = {Anti‐apoptotic protein BCL‐XL as a therapeutic vulnerability in gastric cancer},
  journal = {Animal Models and Experimental Medicine},
  year = {2023},
  doi = {10.1002/ame2.12330}
}
Kostenlos starten →